Eye - retinal vein occlusion

The PBS subsidises aflibercept, dexamethasone, intravitreal implant and ranibizumab for patients with branched or central retinal vein occlusion with macular oedema.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with aflibercept, dexamethasone and ranibizumab under the National Health Act 1953, section 85 for patients with retinal vein occlusion with macular oedema.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing aflibercept, dexamethasone and ranibizumab.

Treatment specifics

Patients must be treated by an ophthalmologist or in consultation with an ophthalmologist to be eligible for PBS subsidised treatment with these medications.

Applications

Initial treatment

Apply for initial authority approval to prescribe PBS subsidised aflibercept, dexamethasone and ranibizumab to treat retinal vein occlusion with macular oedema in writing and either:

All applications must include the completed:

If urgent, you can fax the first authority application to us on 1300 093 177. Our operating hours are Monday to Friday from 8 am to 5 pm AEST. Then the PBS Complex Drugs Programs Team will call you.

Continuing treatment

To apply for continuing PBS subsidised treatment with aflibercept, dexamethasone and ranibizumab call the PBS Complex Drugs Programs enquiry line.

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 17 December 2018